Clinical trial · Observational
The Prognostic Value of PET/CT for Tumor Progression in Patients With Metastatic Hormone-sensitive Prostate Cancer
The Prognostic Value of Quantitative Parameters Derived From Dual Scanning of FDG and PSMA PET/CT for Tumor Progression in Patients With Metastatic Hormone-sensitive Prostate Cancer Receiving Novel Hormone Therapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Investigators retrospectively collected data from consecutive patients treated at the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, from October 2020 to March 2024. The inclusion criteria were as follows: (1) patients with diagnosis of metastatic hormone-sensitive prostate cancer, confirmed by PSA levels, radiographic tests and pathological information; (2) patients who underwent FDG and PSMA PET/CT prior to the initiation of medical treatment. The exclusion criteria were as follows: (1) patients who received novel hormone therapy or a prostate biopsy prior to PET/CT; (2) patients with other malignancies; (3) patients received hormone therapy without NHT; (4) patients received chemotherapy or radiotherapy prior to or during novel hormone therapy; (5) absence of follow-up data at the hospital.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| PET / CT | — | UNRESOLVED | — |
| Prostate Cancer Metastatic Disease | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (4)
- label
- Group1
- description
- PCa40%MTV-P = High, PCa40%MTV-G = Low
- label
- Group2
- description
- PCa40%MTV-P = Low, PCa40%MTV-G = High
- label
- Group3
- description
- PCa40%MTV-P = Low, PCa40%MTV-G = Low
- label
- Group4
- description
- PCa40%MTV-P = High, PCa40%MTV-G = High
Primary outcomes (1)
- measure
- Castration-Resistant Prostate Cancer free survival (CRPC-FS)
- timeFrame
- From date of the initiation of novel hormone therapy until the date of first documented either PSA or radiography-confirmed progression or date of the last follow-up for any cause, whichever came first, assessed up to 100 months
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
Inclusion Criteria: * patients with diagnosis of metastatic hormone-sensitive prostate cancer, confirmed by PSA levels, radiographic tests and pathological information * patients who underwent FDG and PSMA PET/CT prior to the initiation of medical treatment Exclusion Criteria: * patients who received novel hormone therapy or a prostate biopsy prior to PET/CT * patients with other malignancies * patients received hormone therapy without novel hormone therapy * patients received chemotherapy or radiotherapy prior to or during novel hormone therapy * absence of follow-up data at our institution
References
Publications (0)
Data not yet available